Management of infections caused by vancomycin-resistant gram-positive bacteria

Pediatric Infectious Disease Journal

Volumn 29, Issue 7, 2010, Pages 662-664

  Bagga, Bindiya ^a,b   Shenep, Jerry L ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

enterococcus; Grampositive bacteria; Staphylococcus aureus; vancomycin resistance

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; STREPTOMYCIN; SULFATRIMETHOPRIM; TEICOPLANIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARCANOBACTERIUM HAEMOLYTICUM; BACTERIAL GENE; BACTERIUM ISOLATE; BIOFILM; CROSS RESISTANCE; EPIDEMIC; ERYSIPELOTHRIX; GENE EXPRESSION; GRAM POSITIVE BACTERIUM; INFECTION CONTROL; LACTOBACILLUS; LEUCONOSTOC; LISTERIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PEDIOCOCCUS; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT GRAM POSITIVE BACTERIUM; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 77954330555     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181e78efc     Document Type: Review

References (15)

1. Krcmery Jr V, Sefton A. Vancomycin resistance in Gram-positive bacteria.. International J An-timicrob Agents. 2000;14:99-105.
2. Hageman JC, et al. Investigation and control of vancomycin-intermediate and-resistant Staphylo-coccus aureus: A Guide for Health Departments and Infection Control Personnel. Atlanta, GA 2006. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/ar/visa-vrsa-guide.pdf.
3. Sievert DM, et al. Vancomycin-resistant Staphylo-coccus aureus.. Clin Infect Dis. 2008;46:668-674.
4. Finks J, et al. Vancomycin-resistant Staphylococ-cus aureus.. Emerging Infectious Diseases. 2009;15:943-945.
5. LeClercq R, et al. Plasmid-mediated resistance.. NEngl JMed. 1988;319:157-161.
6. Murray BE. What can we do about vancomycin-resistant enterococci. Clin Infect Dis. 1995;20: 1134-1136.
7. Nosocomial enterococci resistant to vancomy-cin\United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42:597-599.
8. Low DE, et al. Clinical prevalence, antimicrobial.. Clin Infect Dis 2001;32(Suppl):S133-S145.
9. Kirst HA, et al. Historical yearly usage.. Antimicrob Agents Chemother. 1998;42:1303-1304.
10. English BK, Shenep JL. Enterococcal and viri-dans streptococcal infections. In: Feigin RD, et al, eds. Textbook of Pediatric Infectious Diseases (Sixth Edition). Philadelphia: WB Saunders Company; 2009:Chapter 95, pp 1258-1288.
11. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000;342:710-721.
12. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin Infect Dis. 2006;42(Suppl 1):S25-S34.
13. Presterl E, et al. The efficacy of teicoplanin.. J Antimicrob Chemother. 1993;31:755-766.
14. Caron F, et al. Comparison of different-lactam-glycopeptide-gentamicin combinations.. J Infect Dis. 1995;171:106-112.
15. Koomanachai P, et al. Newer developments in the treatment of Gram-positive infections. Expert Opin Pharmacother. 2009;10:2829-2843.